ABBOTT INDIA LIMITED

The global companion diagnostic tests in oncology market is projected to grow at a CAGR of 9.5% from 2024 to 2034, reaching $17.0 billion by 2034. Liquid biopsy technologies, AI integration, and patient advocacy drive demand. Key players include Roche Diagnostics, Agilent Technologies, and Foundation Medicine. NGS and EGFR biomarkers lead the market segments.

Abbott launches Aveir DR leadless pacemaker in UK, following CE mark approval in Europe. The dual-chamber system, smaller than a AAA battery, treats abnormal heart rhythms via a minimally invasive procedure, using i2i technology for synchronized pacing.

Cereno Scientific announced an article by BioStock featuring an interview with CEO Sten R. Sörensen on the Orphan Medicinal Product Designation for CS1 in PAH. The article is available [here](https://news.cision.com/cereno-scientific/r/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-including-an-interview-of-c,c4034854).

Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.

Abbott's Lingo, a non-prescription CGM system, tracks glucose in real-time to help users improve health and wellness, offering insights on food, exercise, and stress. It aims to retrain metabolism and enhance overall well-being without diagnosing diseases like diabetes.

MedTech sector innovations in medical devices, diagnostics, digital health, and robotic surgery drive market growth from $456.9B in 2020 to $800B by 2030. AI advancements boost predictive diagnostics, remote monitoring, and precision medicine, projecting a $1.2B medical devices market by 2027. Medtronic plc (MDT), STERIS plc (STE), and Hologic, Inc. (HOLX) are key players, with MDT focusing on cardiovascular, neuroscience, and diabetes solutions, STE emphasizing infection prevention, and HOLX enhancing women's health through diagnostics and surgical products.

Subscribe to BioWorld™ news services.

Abbott's TRANSCEND study evaluates DBS system for treatment-resistant depression (TRD), granted FDA Breakthrough Device designation. DBS, akin to a pacemaker, sends electrical pulses to brain areas affecting depression. The study aims to gather evidence on DBS's impact for TRD patients needing alternative treatments. TRANSCEND is a multi-centered, double-blind, randomized, sham-controlled trial enrolling 100 TRD patients, evaluating DBS's safety and efficacy through MADRS scores.

The FDA categorizes Abbott’s FreeStyle Libre 3 CGM system as a Class I recall due to sensors producing inaccurate glucose readings, potentially causing serious injury or death. Two injuries reported, no deaths.